ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery of HCC Patients

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

In this study, the investigators will detect hepatocellular carcinoma lesions using fluoescence imaging with ITGA6 targeting probes during tumor resection surgery. The aim is to evaluate wether intraoperative fluorescence imaging targeting ITGA6 can help to improve the detction effect of hepatocellular carcinoma, and finally help the accurate surgical resection. The main purposes of this study include: 1. To raise the detection rate of hepatocellular carcinoma intraoperatively using the novel NIR-II fluorescence molecular imaging and the ITGA6 targeting probe. 2. To validate the safety and effectiveness of the proposed ITGA6 targeting probes for clinical application.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:

• Patients who have been diagnosed with hepatocellular carcinoma.

• Planned to receive hepatectomy.

• Liver function Child-Pugh A.

• ITGA6 was validated highly expressed preoperatively.

• Aged 18 to 80, and the expected lifetime is longer than 6 months.

• Approved to sign the informed consent.

Locations
Other Locations
China
Guangdong
RECRUITING
Guangzhou
Sichuan
RECRUITING
Luzhou
Contact Information
Primary
Xiaojing Shi, PhD
shixiaojing2017@ia.ac.cn
13261798652
Time Frame
Start Date: 2024-01-07
Estimated Completion Date: 2039-12-31
Participants
Target number of participants: 90
Treatments
Experimental: RDCy7 Intraoperative Fluorescence
The patients will receive an injection of fluorophore (RDCy7) before the surgery. Then intraoperative fluorescence imaging will be performed to guide lesion resection.
Related Therapeutic Areas
Sponsors
Leads: Institute of Automation, Chinese Academy of Sciences

This content was sourced from clinicaltrials.gov